Yuekang Pharmaceutical YOUCARE wechat public account said: recently, Yuekang Pharmaceutical broad-spectrum coronavirus membrane fusion inhibitor polypeptide drug (YKYYO17 atomization inhalant) was approved by the National Drug Administration for clinical trials. YKYY017 atomization inhalant is an innovative chemical drug developed by the company with clear action mechanism, definite curative effect and complete independent intellectual property rights. The indication for this application is the treatment of novel coronavirus infection.
The clinical approval of the atomization inhalant is of great significance. The peptide drug inhalation preparation is an innovative high-end preparation. The efficient utilization of peptide drugs is realized through inhalation lung delivery, which makes the peptide drugs exert systemic efficacy and has broad application prospects.
YKYY017 aerosolized inhalant is the latest generation of broad-spectrum and efficient coronavirus membrane fusion inhibitor jointly developed by Yuekang Pharmaceutical and the Institute of Pathogenic Biology, Chinese Academy of Medical Sciences. It can play an antiviral role by inhibiting the two membrane fusion pathway of cell surface and endosomal body. Yuekang Pharmaceutical has the global exclusive interest of YKYY017.
At present, the COVID-19 epidemic situation at home and abroad is still grim, and there is an urgent need for effective epidemic prevention and control products. The YKYY017 atomization inhalation agent used for this treatment is a product with independent intellectual property rights and can be used for the treatment of novel coronavirus infection, which will add more power to the protection of people's lives and health.
